DelveInsight’s “Frontotemporal Dementia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Frontotemporal Dementia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Frontotemporal Dementia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Frontotemporal Dementia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Frontotemporal Dementia: An Overview
FTD is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behavior, and language. There are three types of frontotemporal disorders (FTD): behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and movement disorders.
FTD is considered young-onset dementia, occurring mainly between the ages of 45 to 65, and is the most common dementia in those under 60 years of age. FTD occurs when brain cells in the frontal or temporal lobes die due to the build-up of abnormal proteins, leading to abnormal brain function, and more cell deaths result in brain atrophy. FTD encompasses clinical disorders that include changes in behavior, language, executive control, and often motor symptoms.
Frontotemporal Dementia Market Key Facts
-
Upcoming therapy such as AL001 has the potential to create a significant positive shift in the Frontotemporal Dementia market size.
-
The United States accounts for the largest market size of Frontotemporal Dementia, in comparison to the EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
-
Total Frontotemporal Dementia diagnosed prevalent cases in the 7MM were found to be 128,570 in 2021, which might increase by the end of 2032. These cases are expected to increase at a CAGR of 0.3% during the study period (2019–2032).
-
Among 7MM, the United States has the highest Frontotemporal Dementia prevalent cases with 58,960 cases in 2021.
-
On the basis of type-specific diagnosed prevalent cases of Frontotemporal Dementia, bvFTD accounted for the highest number of cases in 2021 with 35,846 cases in the United States.
-
Among the European countries, Germany had the highest Frontotemporal Dementia diagnosed prevalent population with 14,856 cases, followed by France with 11,983 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
-
Japan registered 11,845 diagnosed prevalent cases of Frontotemporal Dementia in 2021.
Frontotemporal Dementia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Frontotemporal Dementia pipeline therapies. It also thoroughly assesses the Frontotemporal Dementia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Frontotemporal Dementia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Frontotemporal Dementia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Frontotemporal Dementia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Frontotemporal Dementia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Frontotemporal Dementia Epidemiology, Segmented as –
-
Total Diagnosed Prevalent cases of Frontotemporal Dementia (FTD) in the 7MM [2019–2032]
-
Type-specific Diagnosed Prevalent cases of Frontotemporal Dementia (FTD) in the 7MM [2019–2032]
-
Gene-specific Diagnosed Prevalent cases of Frontotemporal Dementia (FTD) in the 7MM [2019–2032]
Frontotemporal Dementia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Frontotemporal Dementia market or expected to be launched during the study period. The analysis covers the Frontotemporal Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Frontotemporal Dementia drugs based on their sale and market share.
The report also covers the Frontotemporal Dementia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Frontotemporal Dementia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Frontotemporal Dementia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/frontotemporal-dementia-market
Frontotemporal Dementia Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Frontotemporal Dementia. Currently, Deerland Probiotics & Enzymes is leading the therapeutics market with its Frontotemporal Dementia drug candidates in the most advanced stage of clinical development.
Frontotemporal Dementia Companies Actively Working in the Therapeutics Market Include
-
Alector Inc.
-
Autifony Therapeutics
-
CAMP4 Therapeutics
-
Coya Therapeutics
-
Denali Therapeutics Inc
-
Neurimmune
-
Oncolys BioPharma Inc
-
Passage Bio, Inc.
-
Prevail Therapeutics
-
SOLA Biosciences
-
Transposon Therapeutics, Inc
-
WaVe Life Sciences
And Many Others
Emerging and Marketed Frontotemporal Dementia Therapies Covered in the Report Include:
-
AL001: Alector
-
PBFT02: Passage Bio
-
PR 006: Prevail Therapeutics
-
Latozinemab: Alector
-
PBFT-02: Passage Bio
-
WVE-004: WaVe life Sciences
-
EXO-050: Coya Therapeutics
And Mnay More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/frontotemporal-dementia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Frontotemporal Dementia Competitive Intelligence Analysis
4. Frontotemporal Dementia Market Overview at a Glance
5. Frontotemporal Dementia Disease Background and Overview
6. Frontotemporal Dementia Patient Journey
7. Frontotemporal Dementia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Frontotemporal Dementia Treatment Algorithm, Current Treatment, and Medical Practices
9. Frontotemporal Dementia Unmet Needs
10. Key Endpoints of Frontotemporal Dementia Treatment
11. Frontotemporal Dementia Marketed Therapies
12. Frontotemporal Dementia Emerging Drugs and Latest Therapeutic Advances
13. Frontotemporal Dementia Seven Major Market Analysis
14. Attribute Analysis
15. Frontotemporal Dementia Market Outlook (In US, EU5, and Japan)
16. Frontotemporal Dementia Companies Active in the Market
17. Frontotemporal Dementia Access and Reimbursement Overview
18. KOL Views on the Frontotemporal Dementia Market
19. Frontotemporal Dementia Market Drivers
20. Frontotemporal Dementia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/frontotemporal-dementia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Implantable Cardioverter Defibrillators (ICDs) Market
“Implantable Cardioverter Defibrillators (ICDs) Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Implantable Cardioverter Defibrillators market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Implantable Cardioverter Defibrillators Market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/